Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.

Details

Serval ID
serval:BIB_7B98175BFE96
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Journal
Hypertension
Author(s)
Regamey F., Maillard M., Nussberger J., Brunner H.R., Burnier M.
ISSN
1524-4563[electronic]
Publication state
Published
Issued date
2002
Volume
40
Number
3
Pages
266-72
Language
english
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Abstract
This double-blind placebo-controlled study was designed to investigate the acute and sustained hormonal, renal hemodynamic, and tubular effects of concomitant ACE and neutral endopeptidase (NEP) inhibition by omapatrilat, a vasopeptidase inhibitor, in men. Thirty-two normotensive subjects were randomized to receive a placebo, omapatrilat (40 or 80 mg), or the fosinopril/hydrochlorothiazide (FOS/HCTZ; 20 and 12.5 mg, respectively) fixed combination for 1 week. Blood pressure, renal hemodynamics, urinary electrolytes and atrial natriuretic peptide excretion, and several components of the renin-angiotensin system were measured for 6 hours on days 1 and 7 of drug administration. When compared with the placebo and the FOS/HCTZ combination, omapatrilat induced a significant decrease in plasma angiotensin II levels (P<0.001 versus placebo; P<0.05 versus FOS/HCTZ) and an increase in urinary atrial natriuretic peptide excretion (P<0.01). These hormonal effects were associated with a significant fall in blood pressure (P<0.01) and a marked renal vasodilatation, but with no significant changes in glomerular filtration rate. The FOS/HCTZ markedly increased urinary sodium excretion (P<0.001). The acute natriuretic response to FOS/HCTZ was significantly greater than that observed with omapatrilat (P<0.01). Over 1 week, however, the cumulative sodium excretion induced by both doses of omapatrilat (P<0.01 versus placebo) was at least as great as that induced by the dose of FOS/HCTZ (P=NS versus FOS/HCTZ). In conclusion, the results of the present study in normal subjects demonstrate that omapatrilat has favorable renal hemodynamic effects. Omapatrilat combines potent ACE inhibition with a sustained natriuresis, which explains its well-documented potent antihypertensive efficacy.
Keywords
Adult, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Atrial Natriuretic Factor, Blood Pressure, Double-Blind Method, Hemodynamics, Humans, Kidney, Kidney Tubules, Kinetics, Male, Natriuresis, Neprilysin, Protease Inhibitors, Pyridines, Renal Plasma Flow, Renin-Angiotensin System, Sodium, Thiazepines
Pubmed
Web of science
Open Access
Yes
Create date
05/03/2008 16:39
Last modification date
20/08/2019 14:37
Usage data